NASDAQ:MRTX Mirati Therapeutics - MRTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $51.67 -1.74 (-3.26%) (As of 02/1/2023 01:44 PM ET) Add Compare Share Share Today's Range$49.39▼$53.4750-Day Range$39.81▼$98.6252-Week Range$32.96▼$124.81Volume772,069 shsAverage Volume1.32 million shsMarket Capitalization$2.98 billionP/E RatioN/ADividend YieldN/APrice Target$81.47 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Mirati Therapeutics MarketRank™ ForecastAnalyst RatingHold2.47 Rating ScoreUpside/Downside57.4% Upside$81.47 Price TargetShort InterestBearish18.46% of Shares Sold ShortDividend StrengthN/ASustainability-0.68Upright™ Environmental ScoreNews Sentiment0.38Based on 11 Articles This WeekInsider TradingSelling Shares$8.47 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector521st out of 1,053 stocksPharmaceutical Preparations Industry264th out of 519 stocks 4.3 Analyst's Opinion Consensus RatingMirati Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.47, Mirati Therapeutics has a forecasted upside of 57.4% from its current price of $51.75.Amount of Analyst CoverageMirati Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.46% of the outstanding shares of Mirati Therapeutics have been sold short.Short Interest Ratio / Days to CoverMirati Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Mirati Therapeutics has recently increased by 0.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMirati Therapeutics does not currently pay a dividend.Dividend GrowthMirati Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirati Therapeutics has received a 74.62% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirati Therapeutics is -0.68. Previous Next 1.9 News and Social Media Coverage News SentimentMirati Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Mirati Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for MRTX on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirati Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,465,677.00 in company stock.Percentage Held by InsidersOnly 3.47% of the stock of Mirati Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mirati Therapeutics are expected to remain at ($13.50) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirati Therapeutics is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirati Therapeutics is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirati Therapeutics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mirati Therapeutics (NASDAQ:MRTX) StockMirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Read More Receive MRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRTX Stock News HeadlinesJanuary 31, 2023 | americanbankingnews.comMorgan Stanley Trims Mirati Therapeutics (NASDAQ:MRTX) Target Price to $50.00January 28, 2023 | americanbankingnews.comBrokerages Set Mirati Therapeutics, Inc. (NASDAQ:MRTX) PT at $82.13February 1, 2023 | Investing Trends (Ad)Move Over Lithium – 220 Pounds of Graphite In Every EV BatteryInvestors constantly hear that lithium is the key to powering our transition to electric vehicles and clean energy. Truth is, switching from gas-powered isn't possible without massive amounts of graphite. But America hasn't produced any graphite since the 1950s. Now, a little-known exploration company has defined America's largest high-quality graphite deposit near Nome, Alaska.January 27, 2023 | americanbankingnews.comB. Riley Comments on Mirati Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:MRTX)January 26, 2023 | americanbankingnews.comB. Riley Weighs in on Mirati Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:MRTX)January 25, 2023 | americanbankingnews.comMirati Therapeutics (NASDAQ:MRTX) Price Target Raised to $56.00 at B. RileyJanuary 19, 2023 | finance.yahoo.comMirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133January 19, 2023 | finance.yahoo.comWe're Keeping An Eye On Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn RateFebruary 1, 2023 | Investing Trends (Ad)Move Over Lithium – 220 Pounds of Graphite In Every EV BatteryInvestors constantly hear that lithium is the key to powering our transition to electric vehicles and clean energy. Truth is, switching from gas-powered isn't possible without massive amounts of graphite. But America hasn't produced any graphite since the 1950s. Now, a little-known exploration company has defined America's largest high-quality graphite deposit near Nome, Alaska.January 6, 2023 | benzinga.comKaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the FirmDecember 22, 2022 | finance.yahoo.comMirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 22, 2022 | msn.comMirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRCDecember 14, 2022 | msn.comMirati draws Hold rating at Needham despite recent selloffDecember 13, 2022 | baystreet.caMirati Drops on Acceptance of Cancer DrugDecember 13, 2022 | finance.yahoo.comMirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLCDecember 9, 2022 | benzinga.comWhy Mirati Therapeutics Shares Are NosedivingDecember 9, 2022 | finance.yahoo.comThese Analysts Think Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Sales Are Under ThreatDecember 8, 2022 | benzinga.comWhy Mirati Therapeutics Shares Are Getting Hammered Again TodayDecember 7, 2022 | finance.yahoo.comWhy Shares of Mirati Therapeutics Fell WednesdayDecember 7, 2022 | benzinga.comWhy Mirati Therapeutics Stock Is Trading Sharply Lower TodayDecember 7, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Mirati Therapeutics (MRTX)December 6, 2022 | finance.yahoo.comMirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising EfficacyDecember 6, 2022 | finance.yahoo.comWhy Shares of Mirati Therapeutics Fell TuesdayDecember 6, 2022 | finance.yahoo.comMirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats UpDecember 6, 2022 | barrons.comPremarket Movers: GitLab Cl A, Mirati Therapeutics, TextronDecember 2, 2022 | finance.yahoo.comMirati Therapeutics Announces Update for the Phase 3 SAPPHIRE StudyNovember 29, 2022 | seekingalpha.comMirati Therapeutics: Poised For TakeoffSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRTX Company Calendar Last Earnings11/08/2022Today2/01/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRTX CUSIPN/A CIK1576263 Webwww.mirati.com Phone(858) 332-3410FaxN/AEmployees413Year FoundedN/APrice Target and Rating Average Stock Price Forecast$81.47 High Stock Price Forecast$188.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+57.7%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($13.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-581,780,000.00 Net Margins-6,253.81% Pretax Margin-6,251.66% Return on Equity-60.40% Return on Assets-52.78% Debt Debt-to-Equity RatioN/A Current Ratio9.65 Quick Ratio9.65 Sales & Book Value Annual Sales$72.09 million Price / Sales41.28 Cash FlowN/A Price / Cash FlowN/A Book Value$25.24 per share Price / Book2.05Miscellaneous Outstanding Shares57,590,000Free Float55,589,000Market Cap$2.98 billion OptionableOptionable Beta1.07 Key ExecutivesMr. David D. Meek (Age 60)CEO & Director Comp: $974.53kDr. Charles M. Baum M.D. (Age 65)Ph.D., Founder, Pres, Head of R&D and Director Comp: $1.11MDr. James G. Christensen Ph.D. (Age 55)Exec. VP & Chief Scientific Officer Comp: $784.42kMr. Benjamin J. Hickey M.B.A. (Age 48)Chief Commercial Officer Comp: $769.03kMs. Laurie D. Stelzer (Age 55)Chief Financial Officer Ms. Reena R. DesaiChief Legal Officer & Corp. Sec.Mr. Michael E. Paolucci (Age 63)Chief People Officer Dr. Kelly Covello Ph.D.VP & Head of Medical AffairsMr. Ryan AsayVP & Head of Corp. AffairsDr. Alan Bart Sandler M.D. (Age 66)Exec. VP & Chief Medical Officer More ExecutivesKey CompetitorsBlueprint MedicinesNASDAQ:BPMCInsmedNASDAQ:INSMGalapagosNASDAQ:GLPGHarmony BiosciencesNASDAQ:HRMYAbCellera BiologicsNASDAQ:ABCLView All CompetitorsInsiders & InstitutionsMonaco Asset Management SAMSold 7,015 shares on 1/31/2023Ownership: 0.017%New York State Common Retirement FundBought 50,650 shares on 1/30/2023Ownership: 0.402%Signaturefd LLCSold 804 shares on 1/30/2023Ownership: 0.001%Trellus Management Company LLCBought 6,638 shares on 1/27/2023Ownership: 0.012%Dupont Capital Management CorpBought 1,909 shares on 1/26/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions MRTX Stock - Frequently Asked Questions Should I buy or sell Mirati Therapeutics stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRTX shares. View MRTX analyst ratings or view top-rated stocks. What is Mirati Therapeutics' stock price forecast for 2023? 14 analysts have issued 12-month target prices for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $50.00 to $188.00. On average, they expect the company's share price to reach $81.47 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price. View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts. How have MRTX shares performed in 2023? Mirati Therapeutics' stock was trading at $45.31 at the start of the year. Since then, MRTX shares have increased by 17.9% and is now trading at $53.41. View the best growth stocks for 2023 here. When is Mirati Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our MRTX earnings forecast. How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($3.09) earnings per share for the quarter, topping the consensus estimate of ($3.46) by $0.37. The biotechnology company had revenue of $5.43 million for the quarter, compared to the consensus estimate of $4.72 million. Mirati Therapeutics had a negative net margin of 6,253.81% and a negative trailing twelve-month return on equity of 60.40%. What other stocks do shareholders of Mirati Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU). What is Mirati Therapeutics' stock symbol? Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX." Who are Mirati Therapeutics' major shareholders? Mirati Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include National Bank of Canada FI (0.64%), Allspring Global Investments Holdings LLC (0.41%), New York State Common Retirement Fund (0.40%), Assenagon Asset Management S.A. (0.29%), DekaBank Deutsche Girozentrale (0.03%) and Hennion & Walsh Asset Management Inc. (0.03%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed. View institutional ownership trends. How do I buy shares of Mirati Therapeutics? Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mirati Therapeutics' stock price today? One share of MRTX stock can currently be purchased for approximately $53.41. How much money does Mirati Therapeutics make? Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $3.08 billion and generates $72.09 million in revenue each year. The biotechnology company earns $-581,780,000.00 in net income (profit) each year or ($13.39) on an earnings per share basis. How many employees does Mirati Therapeutics have? The company employs 413 workers across the globe. How can I contact Mirati Therapeutics? Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com. This page (NASDAQ:MRTX) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.